Tagged with GEN

Artificial Intelligence IBM Watson Health’s Director for Global Life Sciences & Go-To Market Leader for Europe & Asia Pacific Christina Busmalis gives her insights into how AI and greater utilisation of real-world evidence is shaping the global biopharmaceutical industry, including the tangible results she has seen so far, and the lengthy path…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Europe Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial resistance (AMR). A panel of experts from diverse backgrounds at the European Health Forum Gastein put their heads together to…

Switzerland Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company.   As one of the first companies in the developing world to branch out into this segment – launching four biosimilar products between 2001 and 2011 –…

UAE LIFEPharma, a subsidiary of UAE-based VPS Healthcare, has signed a Dh 200 million (USD 55 million) deal with Canada’s Apotex to produce 120 million generic tablets and medicines for Motor Neurone Disease annually over the next 10 years.   This partnership is an important milestone, not only for LIFEPharma and…

Sweden Judith Love, country president Sweden and oncology general manager for the Nordics region for Novartis, underlines the need for a new reimbursement system for cell and gene therapies in the region and explains how the Nordics and Sweden can be a pioneer in this field, by initiating early dialogue between…

China Geoff Kau, Co-GM and CSO of Ping An Smart City, introduces the breathtaking breadth of the Ping An healthcare ecosystem, and the interesting projects his subsidiary, Ping An Smart City, is working on to promote efficiency and efficacy within the healthcare system for patients, payers and providers. He shares a…

USA BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New Jersey. Hart also outlines how BioNJ is hoping to continue to grow the region’s reputation as a hub that stands out for its level of expertise, favourable geographic…

China China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve the unmet needs of patients with their cutting-edge technologies in cardiology, immunology and more.   Adagene Adagene’s founder and CEO…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…

Europe Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its members are working to tackle the issue of drug shortages across the continent, and the crucial importance of establishing a high-level dialogue between industry and governments. Adrian van den…

Opinion Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a prediction for the industry’s future, including a significantly increased amount of interplay between large technology and pharma companies.   The past two decades have seen an explosion of biomedical…